Acute myeloid leukemia
Conditions
Interventions
Control group:None
Sponsors
Lanzhou University First Clinical Medical College
Eligibility
Sex/Gender
All
Age
45 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. AML group: AML patients who were hospitalized in the Department of Hematology of the First Hospital of Lanzhou University from December 2025 to June 2026 and completed the first consolidation chemotherapy were selected. 2. Control group: 25 cases with no confirmed FX deficiency, normal coagulation function and no recent infection were selected as the control group (single blood collection). Match by age and gender. The age was stratified and matched in 5-year intervals. For example, the median age of the AML group was 50 years old, and the healthy group was matched with 45 to 55 years old. The gender was consistent with that of the AML group in the male-to-female ratio.
Exclusion criteria
Exclusion criteria: 1. Exclude cases of blood calcium abnormalities, severe infections, bleeding complications, emergency intervention, and hematopoietic stem cell transplantation during the course of the disease. Both AML group and control group patients had no history of liver and kidney disease, abnormal liver and kidney function, cardiovascular and cerebrovascular disease, or family history of thrombosis; No history of using anticoagulant drugs (such as dabigatran etexilate, argatroban, bivalirudin) or surgery within 2 weeks; No history of whole blood or plasma transfusion within 2 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dynamic changes in pFXIII-A2 and pFXIII-B2 levels;Bleeding events;Chemotherapy response (complete remission rate, CR);Progression-free survival (PFS);Overall survival (OS);Event-free survival (EFS);Thrombotic events; | — |
Countries
china
Contacts
Public ContactLi Zijian
Lanzhou University First Clinical Medical College
Outcome results
None listed